Oral immunization of mice with recombinant Lactococcus lactis expressing Cu,Zn superoxide dismutase of Brucella abortus triggers protective immunity

Vaccine

Volumn 30, Issue 7, 2012, Pages 1283-1290

  Sáez, Darwin ^a   Fernández, Pablo ^a   Rivera, Alejandra ^a   Andrews, Edilia ^a   Oñate, Angel ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Brucella abortus; Brucellosis; Interleukin 12; Recombinant Lactococcus lactis; Recombinant vaccine; Superoxide dismutase

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BRUCELLA ABORTUS; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; LACTOCOCCUS LACTIS; LUNG LAVAGE; LYMPHOCYTE PROLIFERATION; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SPLEEN CELL; VACCINATION; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; DNA, BACTERIAL; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN-12; LACTOCOCCUS LACTIS; MICE; MICE, INBRED BALB C; PLASMIDS; SUPEROXIDE DISMUTASE; VACCINATION;

EID: 84856568820     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.088     Document Type: Article

References (72)

1. Corbel M.J. Brucellosis: an overview. Emerg Infect Dis 1997, 3(2):213-221.
2. Gorvel J.P. Brucella: a Mr " Hide" converted into Dr. Jekyll. Microbes Infect 2008, 10:1010-1013.
3. Guzman-Verri C., Manterola L., Sola-Landa A., Parra A., Cloeckaert A., Garin J., et al. The two-component system BvrR/BvrS essential for Brucella abortus virulence regulates the expression of outer membrane proteins with counterparts in members of the Rhizobiaceae. Proc Natl Acad Sci USA 2002, 99:12375-12380.
4. Moreno E., Moriyon I. Brucella melitensis: a nasty bug with hidden credentials for virulence. Proc Natl Acad Sci USA 2002, 99:1-3.
5. Ratushna V.G., Sturgill D.M., Ramamoorthy S., Reichow S.A., He Y., Lathigra R., et al. Molecular targets for rapid identification of Brucella spp. BMC Microbiol 2006, 6:13-33.
6. Boschirolli M., Foulingne V., O'Callaghan D. Brucellosis: a world-wide zoonosis. Curr Opin Microbiol 2001, 4:58-64.
7. Zhan Y., Yang J., Cheers C. Cytokines response of T-cell subset from Brucella abortus-infected mice to soluble Brucella protein. Infect Immun 1993, 61:2841-2847.
8. Araya L.N., Elzer P.H., Rowe G.E., Enright F.M., Winter A.J. Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol 1989, 143:3330-3337.
9. Corner L.A., Alton G.G. Persistance of Brucella abortus strain 19 infection in adult cattle vaccinated with reduced doses. Res Vet Sci 1981, 31:342-344.
10. Palmer M.V., Cheville N.F., Jensen A.E. Experimental infection of pregnant cattle with the vaccine candidate Brucella abortus strain RB51: pathologic, bacteriologic, and serologic findings. Vet Pathol 1996, 33:682-691.
11. Ashford D.A., di Pietra J., Lingappa J., Woods C., Noll H., Neville B., et al. Adverse events in humans associated with accidental exposure to the livestock brucellosis. Vaccine 2004, 22:3435-3439.
12. Gilbert C., Robinson K., Le Page R.W., Wells J.M. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect Immun 2000, 68:3251-3260.
13. Hirt H., Erlandsen S.L., Dunny G.M. Heterologous inducible expression of Enterococcus faecalis pCF10 aggregation substance Acs10 in Lactococcus lactis and Streptococcus gordonii contributes to cell hydrophobicity and adhesion to fibrin. J Bacterial 2000, 182:2299-2306.
14. Xin K.Q., Hoshino Y., Toda Y., Igimi S., Kojima Y., Jounai N. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV envelopment. Blood 2003, 102:223-228.
15. Bermúdez-Humarán L.G., Cortes-Pérez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., et al. A novel mucosal vaccine base on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against Human Papillomavirus Type I6-induced tumors. J Immunol 2005, 175:7297-7302.
16. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and challenger. Nat Rev Immunol 2006, 6:148-158.
17. Audouy S.A., van Selm S., van Roosmalen M.L., Post E., Kanninga R., Neef J., et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007, 25:2497-2506.
18. Bahey-El-Din M., Griffin B.T., Gahan C.G. Nisin inducible production of listeriolysin O in Lactococcus lactis NZ9000. Microb Cell Fact 2008, 7:24-34.
19. Mierau I., Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005, 68:705-717.
20. Liu S., Li Y., Xu Z., Wang Y. Immune responses elicited in mice with recombinant Lactococcus lactis expressing F4 fimbrial adhesin FaeG by oral immunization. Vet Res Commun 2010, 34:491-502.
21. Klijn N., Weerkamp A.H., de Vos W.M. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl Environ Microbiol 1995, 61:2771-2774.
22. Lee M.H., Roussel Y., Wilks M., Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001, 19:3927-3935.
23. Bermúdez-Humarán L.G., Langella P., Myoshi A., Gruss A., Tamez-Reyes R.S., Montes de Oca-Luna R.Y., et al. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 2002, 68:917-922.
24. Lui V.W., Falo L.D., Huang L. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. J Gene Med 2001, 3:384-393.
25. Enouf V., Langella P., Commissaire J., Cohen J., Corthier G. Bovine rotavirus nonstructural protein 4 produce by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 2001, 67:1423-1428.
26. Lee H.K., Zamora M., Linehan M., Iijima N., Gonzalez D., Haberman A., et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. J Exp Med 2009, 206:359-370.
27. Barth H., Klein R., Berg P.A., Weidenmann B., Hopf U., Berger T. Induction of T helper cell type 1 response and elimination of HBeAg during treatment with IL-12 in a patient with therapy-refractory chronic hepatitis B. Hepatogastroenterology 2001, 48:553-555.
28. Hultgreen O.H., Stenson M., Tarkowski A. Role of IL-12 in Staphylococcus aureus-triggered arthritis and sepsis. Arthritis Res 2001, 3:41-47.
29. Park A.Y., Hondowics B., Kopf M., Scott P. The role IL-12 in maintaining resistance to Leishmania mayor. J Immunol 2002, 168:5771-5777.
30. Bermúdez-Humarán L.G., Langella P., Corte-Perez N., Gruss A., Tamez-Guerra R.S., Oliveira S., et al. Intranasal Immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003, 71:1887-1896.
31. Oliveira S.C., Splitter G.A. Subcloning and expression of the Brucella abortus L7/L12 ribosomal gene and T-lymphocyte recognition of the recombinant protein. Infect Immun 1994, 62:5201-5204.
32. Vemulapalli R., He Y., Boyle S.M., Sriranganathan N., Schurig G.G. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect Immun 2000, 68:3286-3289.
33. Oliveira S.C., Harms J.S., Rech E.L., Rodarte R.S., Bocca A.L., Goes A.M., et al. The role of T cell subset and cytokines in the regulation of intracellular bacterial infection. Braz J Med Biol Res 1998, 31:77-84.
34. Oñate A., Folch H. 18.5Kd protein. An interesting antigen of Brucella. Arch Med Vet 1995, 27:93-102.
35. Bae J. Generation of baculovirus-Brucella abortus heat shock protein recombinants; mouse immune responses against the recombinants, and B. abortus superoxide dismutase and L7/L12 recombinant proteins. Ph.D. Thesis. Virginia Polytechnic Institute and State University, Blacksburg; 1990.
36. Tabatabai L.B., Pugh G.W. Modulation of immune responses in BALB/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine. Vaccine 1994, 12:919-924.
37. Langella P., Le Loir Y., Ehrlich S.D., Gruss A. Efficient plasmid mobilization by pIP501 in Lactococcus lactis subsp. lactis. J Bacteriol 1993, 175:5806-5813.
38. Schurig G.G., Roop R.M., Bagchi T., Boyle S., Buhrman D., Sriranganathan N. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol 1991, 28:171-188.
39. Oñate A.A., Vemulapalli R., Andrews E., Schurig G.G., Boyle S., Folch H. Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus. Infect Immun 1999, 67:986-988.
40. Oñate A.A., Céspedes S., Cabrera A., Rivers R., González A., Muñoz C., et al. A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2003, 71:4857-4861.
41. Oñate A., Andrews E., Beltran A., Eller G., Schurig G., Folch H. Frequent exposure of mice to crude Brucella abortus proteins down-regulates immune response. J Vet Med B 2000, 47:677-682.
42. Cataldi A., Yevsa T., Vilte D.A., Schulze K., Castro-Parodi M., Larzábal M., et al. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine 2008, 26(44):5662-5667.
43. McGhee J.R., Mestecky J. In defense of mucosal surface. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect Dis Clin N Am 1990, 4:315-341.
44. Chen H. Recent advances in mucosal vaccine development. J Control Release 2000, 67:117-128.
45. Ouwehand A., Isolauri E., Salmine S. The role of the intestinal microflora for the development of the immune system in early childhood. Eur J Nutr 2002, 41:32-37.
46. Ahmed F.E. Genetically modified probiotic in foods. Trends Biotechnol 2003, 21:491-497.
47. Yam K.K., Pouliot P., N'diaye M.M., Fournier S., Olivier M., Cousineau B. Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. Vaccine 2008, 26:2689-2699.
48. Adel-Patient K., Ah-Leung S., Creminon C., Nouaille S., Chatel J.M., Langella P., et al. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 2005, 35:539-546.
49. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995, 13:251-276.
50. Gherardi M.M., Ramirez J.C., Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type I Env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 2000, 74:6278-6286.
51. Metzger D.W., McNutt R.M., Collins J.T., Buchanan J.M., Van Cleave V.H., Dunnick W.A. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms. Eur J Immunol 1997, 27:1958-1965.
52. Cho H.J., Shin H.J., Hanm I.K., Jung W.W., Kim Y.B., Sul D., et al. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine 2007, 25:8049-8057.
53. Li Y.J., Ma G.P., Li G.W., Qiao X.Y., Ge J.W., Tang L.J., et al. Oral vaccination with the porcine rotavirus VP4 outer capsid protein expressed by Lactococcus lactis induces specific antibody production. J Biomed Biotechnol 2010, 708460.
54. Zhang Q., Zhong J., Huan L. Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination. Microbiol Res 2011, 166:111-120.
55. Ko J., Splitter G. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev 2003, 16:65-78.
56. Golding B., Scott D.E., Scharf O., Huang L.Y., Zaitseva M., Lapham C., et al. Immunity and protection against Brucella abortus. Microbes Infect 2001, 3:43-48.
57. Arulanandam B.P., O'Toole M., Metzger D.W. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 1999, 180:940-949.
58. Lynch J.M., Briles D.E., Metzger D.W. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 2003, 71:4780-4788.
59. Sabirov A., Metzger D.W. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 2006, 24:5584-5592.
60. Buchanan R.M., Arulanandam B.P., Metzger D.W. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol 1998, 161:5525-5533.
61. Buchanan R.M., Briles D.E., Arulanandam B.P., Westerink M.A., Raeder R.H., Metzger D.W. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 2001, 19:2020-2028.
62. Arulanandam B.P., Lynch J.M., Briles D.E., Hollingshead S., Metzger D.W. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001, 69:6718-6724.
63. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994, 263:235-237.
64. Staats H.F., Ennis F.A. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J Immunol 1999, 162:6141-6147.
65. Onate A.A., Donoso G., Moraga-Cid G., Folch H., Cespedes S., Andrews E. An RNA vaccine based on recombinant Semliki Forest Virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun 2005, 73:3294-3300.
66. Saez D., Guzman I., Andrews E., Cabrera A., Onate A.A. Evaluation of Brucella abortus DNA and RNA vaccines expressing Cu-Zn superoxide dismutase (SOD) gene in cattle. Vet Microbiol 2008, 129:396-403.
67. Singha H., Mallick A.I., Jana C., Fatima M., Chaudhuri P. Co-immunization with interleukin-18 enhances the protective efficacy of liposomes encapsulated recombinant Cu-Zn superoxide dismutase protein against Brucella abortus. Vaccine 2011, 29:4720-4727.
68. Yu D.H., Hu X.D., Cal H., Li M. A combined DNA vaccine encoding BCSP31, SOD and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL response. DNA Cell Biol 2007, 26:435-443.
69. Gonzalez-Smith A., Vemulapalli R., Andrews E., Onate A.A. Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2. Immunobiology 2006, 211:65-74.
70. Singha H., Mallick A.I., Jana C., Isore D.P., Goswami T.K., Srivastava S.K., et al. Escheriosomes entrapped DNA vaccine co-expressing Cu/Zn superoxide dismutase and IL-18 confers protection against Brucella abortus. Microb Infect 2008, 10:1089-1096.
71. Rajasekaran P., Surendran N., Seleem M., Sriranganathan N., Schurig G., Boyle S.M. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge. Vaccine 2011, 29:3106-3110.
72. Pasquevich K.A., Estein S.M., García-Samartino C., Zwerdling A., Coria L.M., Barrionuevo P., et al. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect Immun 2009, 77(1):436-445.